‘Too elegant to ignore’: Novo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies

Kyle LaHucik

Senior Reporter

A Canadian biotech creating bioprinted tissue therapeutics for type 1 diabetes, obesity and other endocrine and metabolic disorders has raised $115 million in a Series …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘Too elegant to ignore’: Novo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Versant unveils Light Horse with $62M and a partnership with Novartis

Coave raises €32M Series A despite being two years away from the clinic

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

‘Too el­e­gant to ig­nore’: No­vo-al­lied As­pect Biosys­tems nabs $115M for bio­print­ed tis­sue ther­a­pies

Senior Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

‘Too elegant to ignore’: Novo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies